These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1524 related items for PubMed ID: 23980084

  • 1. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.
    J Clin Oncol; 2013 Oct 01; 31(28):3517-24. PubMed ID: 23980084
    [Abstract] [Full Text] [Related]

  • 2. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.
    J Clin Oncol; 2013 Oct 01; 31(28):3509-16. PubMed ID: 23980090
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z.
    Lancet Oncol; 2009 Jan 01; 10(1):25-34. PubMed ID: 19095497
    [Abstract] [Full Text] [Related]

  • 5. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
    Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW.
    Clin Cancer Res; 2012 Apr 01; 18(7):2090-8. PubMed ID: 22238246
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM.
    J Hepatol; 2012 Oct 01; 57(4):821-9. PubMed ID: 22727733
    [Abstract] [Full Text] [Related]

  • 7. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM.
    J Hepatol; 2017 Jun 01; 66(6):1166-1172. PubMed ID: 28131794
    [Abstract] [Full Text] [Related]

  • 8. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
    Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul JL.
    Clin Cancer Res; 2011 Apr 01; 17(7):1973-83. PubMed ID: 21349999
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J.
    J Hepatol; 2013 Dec 01; 59(6):1271-7. PubMed ID: 23928403
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
    Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E.
    J Clin Oncol; 2013 Nov 10; 31(32):4067-75. PubMed ID: 24081937
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Li J, Wang L, Cong N, Shi C, Bu W, Song J, Chen H.
    Hepatogastroenterology; 2014 Jun 10; 61(132):954-7. PubMed ID: 26158148
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ, Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, Byun KS.
    J Clin Gastroenterol; 2014 Mar 10; 48(3):e22-9. PubMed ID: 24045282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.